Why Current Ebola Outbreak Is Hard to Contain

Since May, a rare form of Ebola caused by the Bundibugyo virus has infected more than 11,000 people and claimed thousands of lives in the Democratic Republic of the Congo (DRC), with the outbreak on track to become the largest in recorded history.

This month marked a grim milestone, with more than 5,000 deaths in the in the DRC since the outbreak began. Reports also emerged of the first confirmed case of a UK national infected with the disease, who returned to the UK for treatment at the Royal Free Hospital.

Against this backdrop, two Imperial experts recently shared their insights on how the Ebola outbreak is evolving, the challenges facing responders and affected communities, and what may come next. Here's what we learned.

How big is the current Ebola outbreak?

The outbreak is larger than we thought and will last well into next year.

Professor Neil Ferguson, is among those leading rapid response modelling efforts. His team is currently working closely with local and international partners on: real time modelling of the outbreak, scenario modelling of vaccine deployment, and health economic analyses. Their initial analysis of the epidemic (up to June) recently published in the journal Science.

"One of the major challenges at the moment is we think we're probably only detecting about half of cases which are occurring," said Professor Ferguson, Director of the Jameel Institute for Disease and Emergency Analytics, and Director of the School of Public Health at Imperial. He explained about two-thirds of deaths from the outbreak are happening in the community, and many of these people may not come forward for healthcare. "The priority at the moment is improving detection of cases," he adds.

Professor Ferguson warns that the DRC outbreak is already comparable in scale to the 2014-15 West Africa epidemic and could ultimately become the largest Ebola outbreak on record. Based on current trends, transmission may still be occurring a year from now.

But there are significant challenges in tracking the outbreak, including the sheer size and remoteness of affected regions and the inherent logistical challenges.

"To put it into context, the Ituri and North Kivu provinces – the worst affected – are both the size of small European countries," explained Professor Ferguson. "These are huge areas with limited infrastructure, a very challenging security environment, they are very poor areas and because of their history, there's very low community trust in authorities, in government and even in health authorities."

Why has the DRC been so badly affected?

Conflict, poor health coverage, and endemic disease have all worsened the situation.

The Eastern DRC, where the outbreak originated, has seen decades of armed conflict, insecurity and the displacement of hundreds of thousands of people, and regular outbreaks of cholera, measles and malaria have also taken a heavy toll. This combination has resulted in an epidemic occurring on top of existing humanitarian and health crises, explains Dr Aula Abbara, from Imperial's Department of Infectious Disease.

"This is all occurring in a time of severe funding cuts…and it's estimated more than 14 million people in the DRC are already in need of humanitarian assistance, many of whom live in the affected areas," said Dr Abbara, an Honorary Clinical Associate Professor at Imperial, as well as a Consultant in Infectious Diseases at Imperial College Healthcare NHS Trust and an advisor to Médecins Sans Frontières.

"I was in North Kivu in June of this year," she adds, "I'm an experienced humanitarian and I was struck by the degree of severe malnutrition and the multiple co-existing outbreaks in areas where we're also preparing and responding to this Ebola virus disease outbreak."

What are the challenges with the Bundibugyo virus?

Ebola isn't always haemorrhagic (bleeding and bruising) so can be difficult to diagnose early on.

"As a healthcare worker, it's very difficult to differentiate between BVD [Bundibugyo Viral Disease] and other infections often seen in these areas – whether it's malaria, typhoid or others – because the initial symptoms are non-specific," Dr Abbara explained. "It's a fever, its' fatigue, it's joint pains, it's diarrhoea, it's vomiting and so it could be mistaken for many other diseases in the early phases."

In addition, suitable treatments and medical resources are in short supply, she explains: "BVD was last seen in Uganda in 2007, and in the DRC in 2012, and unfortunately what that means is all the recent licensed Ebola vaccines and monoclonal antibodies are targeting the Zaire strain rather than the Bundibugyo strain that we're dealing with at the moment."

What are the challenges facing healthcare workers?

Beyond the direct risk of infection, healthcare workers risk heat exhaustion from equipment, and additional strain on struggling services.

"Wearing full PPE limits the time that a healthcare worker can be in a facility down to about 45 minutes, perhaps 60 minutes," explained Dr Abbara. "These are very tropical areas where the outbreak's occurring and that can lead to heat exhaustion, dehydration, and manual dexterity becomes very difficult because you're wearing two gloves. You're also wearing goggles. It becomes very cumbersome to work in these settings. And it means that there's less time for patients."

She highlighted how typical clinical tasks, such as changing IV lines and adjusting fluids, become more difficult, which can have a significant impact, especially on children. Resources are also sparse, meaning the majority of patients often won't get access to 'best supportive care' – stabilising vitals, relieving pain, and enabling them to fight the infection.

But the impact of the outbreak includes the indirect costs on a health system that was already under severe strain. As Dr Abbara highlights: "the impacts on children, particularly young children of both BVD and other diseases are severe and can lead to a worse illness and higher mortality; others who are vulnerable are also pregnant women who may also experience interrupted maternity care due to the outbreak."

Among the challenges are trust and misinformation, which can discourage people from seeking care, particularly when communities see substantial resources directed towards Ebola while other longstanding health threats continue to cause suffering.

"Fear is keeping people away from healthcare," explains Dr Abbara, "so indirect deaths, as often in these situations, is substantial."

How soon could we get new vaccines and treatments?

While current treatment options may be limited, trials are underway which could help to turn the tide.

"Clinical trials have started recently testing the existing Ervebo Ebola vaccine, but also potentially two candidate vaccines being developed," explained Professor Ferguson, referencing candidates from the University of Oxford and an RNA vaccine from Moderna.

"Those trials should read out early next year, and allow rollout of vaccination probably from late February, early March onwards," he added. "In addition, there are clinical trials and treatments underway which probably should read out faster."

Dr Abbara added that different therapeutics are being assessed, including the antiviral Remdesivir (which became a central treatment during the COVID-19 pandemic) as well as an experimental pan-Ebolavirus antibody (MBP134) which could target multiple strains. Other teams are trialling the oral antiviral Obeldesivir to reduce the risk of infection among those who have been exposed to the virus (post-exposure prophylaxis). But challenges remain, including ensuring the right groups are included in trials.

"Often children and pregnant women are excluded [from trials]. But of course, they're among those at highest risk of a poor outcome should they be exposed to an ebolavirus," explains Dr Abbara. "Additionally, in terms of the availability of sufficient doses of these therapeutics, they're not necessarily available to meet the need that there is in this current outbreak."

Both Imperial experts stressed that controlling the outbreak will depend not only on medical interventions, but also on building trust with affected communities and supporting local healthcare workers.

Professor Ferguson concluded: "Clearly, both vaccines and effective treatments would aid the response, but neither is a panacea."

Dr Abbara added: "What we need is not only careful surveillance, medical care and diagnostics – all essential in an outbreak, but we must also work to build trust with the communities affected, reduce stigma and work very closely with the local responders to support healthcare access and trust in the services offered. Without these, people will be too afraid to access services, and we know that late presentation can contribute to poorer outcomes."

-

The comments were made at an Imperial media briefing on the outbreak.

Imperial College London is at the frontier of rapid response modelling, real-time tracking, and epidemiological analysis for global disease outbreaks. Our infectious disease experts apply cutting-edge science to address the unmet clinical needs for infectious disease control on a global scale. We also recently created a Biosecurity Network of Excellence to tackle the growing threats to human, animal and plant health.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.